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Background: The purpose of the present study was to retrospectively evaluate whether copy number changes of
the genes encoding the ribonucleotide reductase subunit M1 (RRM1) and/or subunit M2B (RRM2B) predict
sensitivity to gemcitabine administered in combination with docetaxel compared to single agent docetaxel in
advanced breast cancer patients.
Methods: Primary tumor samples from patients randomly assigned to gemcitabine plus docetaxel or docetaxel
alone were analyzed for RRM1 and RRM2B copy number changes using Fluorescence In Situ Hybridization (FISH)
technology with probes covering respectively RRM1 at 11p15.5 and a reference probe covering the centromere of
chromosome 11 (CEN-11), and RRM2B at 8q22.3 and a reference probe covering the centromere of chromosome 8
(CEN-8). The assays were validated in a material of 60 normal breast samples. Time to progression (TTP) was the
primary endpoint. Overall survival (OS) and response rate (RR) were secondary endpoints. Associations between
RRM1/CEN-11 and/or RRM2B/CEN-8 ratios and time-to-event endpoints were analyzed by unadjusted and adjusted
Cox proportional hazards regression models. Heterogeneity of treatment effects on TTP and OS according to gene
status were investigated by subgroup analyses, and the Wald test was applied. All statistical tests were two-sided.
Results: FISH analysis for both RRM1 and RRM2B was successful in 251 patients. RRM1 and RRM2B aberrations
(deletions and amplifications) were observed in 15.9% and 13.6% of patients, respectively. RRM1 aberrations
were associated with a decreased OS in the time interval 1.5-7.4 years (hazard ratio = 1.72, 95% confidence
interval = 1.05-2.79, P = 0.03). RRM2B aberrations alone or in combination with RRM1 aberrations had no
prognostic impact in terms of TTP or OS. RR was not different by gene status. No significant differences were
detected in TTP or OS within subgroups according to gene status and chemotherapy regimen.
Conclusions: This study demonstrated the presence of RRM1 and RRM2B copy number changes in primary
breast tumor specimens. Nevertheless, we found no support of the hypothesis that aberrations of RRM1 or
RRM2B, neither individually nor in combination, are associated with an altered clinical outcome following
chemotherapy with gemcitabine in combination with docetaxel compared to docetaxel alone in advanced
breast cancer patients.
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Ribonucleotide reductase (RNR) catalyzes the formation
of deoxyribonucleotides, thus is a key enzyme during
DNA synthesis and repair [1,2], and is the specific cellular
target of gemcitabine [3]. Mammalian cells enclose three
non-identical subunits of RNR: one homodimeric large
subunit (RRM1) carrying the catalytic site, and two vari-
ants of a homodimeric small subunit (RRM2 and RRM2B)
containing a tyrosyl free radical essential for catalysis [1,2].
As a nucleoside analogue, gemcitabine is intracellularly
phosphorylated into the active metabolite gemcitabine
diphosphate, which is recognized by RNR as a normal
substrate and reacts with the substrate-binding catalytic
site of the RRM1 subunit thereby inactivating the enzyme
[3-5]. Preclinical research has indicated that increased
tumor expression of RRM1 is the major determinant of
resistance to gemcitabine [6], and two cell line studies
have demonstrated an association between gemcitabine
resistance and gene amplification of RRM1 [7,8]. In ad-
dition, low/negative RRM1 mRNA and protein levels
have been reported to correlate significantly with higher
response rate and a better prognosis in lung cancer
patients treated with gemcitabine-based chemotherapy,
and in pancreatic and biliary cancer patients treated
with gemcitabine alone [6,9]. However, there are reports,
including a prospectively conducted phase III clinical
trial, of RRM1 either not being significantly associ-
ated or possibly oppositely associated with survival in
lung cancer patients receiving a gemcitabine-contain-
ing regimen [10-13]. A possible association between
mRNA and protein expression of RRM2 or the RRM2B
subunit and the effect of gemcitabine is less well stud-
ied and has not been addressed in properly sized ran-
domized trials and results from pilot trials are inconsistent
[10,14-18].
Thus, an unambiguous association has not been estab-
lished between mRNA and protein expression of RNR
and benefit from gemcitabine. The underlying copy num-
ber changes of the genes encoding the subunits of RNR
may be determined more reproducible. To address this
issue, gene copy number alterations of the enzyme sub-
units as determined by Fluorescence In Situ Hybridization
(FISH) technology were evaluated in archival primary
tumor samples from patients with locally advanced and
metastatic breast cancer randomized to docetaxel alone
(D) versus gemcitabine plus docetaxel (GD) [19]. Sec-
ondarily, the overall prognostic impact of RNR gene copy
number variation in these patients receiving chemotherapy
was investigated. Furthermore, as chromosomal instability
and copy number alterations have previously been reported
to be more prone to accumulate in highly proliferative
subtypes (i.e. non-luminal A) [20,21], we analyzed the
genomic landscape of RNR gene copy number changes in
relation to PAM50 classified intrinsic subtypes (Jørgensenet al. manuscript provisionally accepted for publication)
to investigate subtype specific patterns.
Methods
The patient study cohort
The Danish Breast Cancer Cooperative Group (DBCG)
phase III multicenter 0102 trial randomized 337 women
with advanced breast cancer to D versus GD. The trial
has been described in detail previously [19]. Patients
were randomly assigned to D (100 mg/m2) day 1, or G
(1000 mg/m2) days 1 and 8 plus D (75 mg/m2) day 8,
every 3 weeks. Prior chemotherapy with a non-taxane
regimen was allowed either adjuvant or as first-line. The
study was conducted in accordance with the Declaration
of Helsinki, and all patients gave their signed informed
consent prior to study entry. DBCG prepared the original
protocol as well as the biomarker supplement, and the
Danish National Committee on Biomedical Research
Ethics approved the original protocol in addition to the
add-on (KF-02-045-01 and KF-12-315632/H-KF-02-
045-01) before activation.
Specimen collection
Formalin-fixed, paraffin-embedded (FFPE) primary tumor
blocks from participating patients were retrospectively
collected from the archives of pathology departments
throughout hospitals of Denmark. All samples were ana-
lyzed as tissue microarrays (TMAs), except six samples
analyzed as whole sections because of small tumor size.
Areas from the periphery of invasive tumor in donor blocks
were identified on haematoxylin-eosin stained sections
and TMAs were designed in the same manner as described
previously [22]. From available and suitable blocks, 2.0 mm
core TMAs were constructed by means of a TMA builder
(Beecher Instrument ATA-27) by a histopathology skilled
biologist (CLTJ) under supervision of a pathologist (EB).
Consecutive 3 μm sections from each TMA block and the
six whole tissue blocks were cut for processing of FISH.
Assay validation cohort
For assay validation we analyzed the RNR candidate gene
copy number variation in 60 TMA samples of normal
breast gland tissue as previously described in Nielsen et al.
2011 [23].
Pilot study
A pilot study was conducted to evaluate the existence of
copy number changes of the genes encoding the subunits
of RNR (RRM1, RRM2, RRM2B) as determined by FISH
in primary tumor samples from 49 of the 337 advanced
breast cancer patients treated with D versus GD [19].
Genetic aberrations were observed regarding RRM1 and
RRM2B (data not shown). Despite the fact that a relation-
ship between the expression of the RRM2 subunit and
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changes were found regarding RRM2 during the pilot
study (data not shown), and further evaluation of the
entire cohort concerned RRM1 and RRM2B copy number
changes only.
RRM1 and RRM2B FISH assay development
The FISH assays were developed based on bacterial artifi-
cial chromosome (BAC) DNA fluorescent probes covering
the sequence of the RRM1 gene at 11p15.5 (BAC clones
RP11-23F23 and RP11-982G19) and the RRM2B gene
at 8q22.3 (BAC clone RP11-318G5), respectively. As
reference, centromeric Peptide Nucleic Acid (PNA) probes
specific for chromosome 11 (CEN-11) and 8 (CEN-8) were
applied. The RRM1 and RRM2B targeted BAC clones were
labeled with Texas Red fluorochrome by Nick translation.
Centromere targeted reference probes were based on a
mixture of PNA oligoes labeled with fluorescein iso-
thiocyanate. As blocking agent a mixture of alu PNA
oligoes was used.
FISH analysis
FISH analysis was performed on samples from tumor
tissue and normal tissue using Dako Histology FISH
accessory kit (K5599, Dako A/S, Glostrup, Denmark)
according to the manufacturer’s instructions and as de-
scribed previously [23]. Evaluation of slides was done
according to the topoisomerase II-alpha (TOP2A) FISH
scoring guidelines (from Dako K5333 USA package insert,
1st edition 2008.01.18). Sufficient nuclei were included
until a total of 60 red gene probe signals were counted
along with the green reference probe signals in the corre-
sponding nuclei. The ratio was calculated as the number
of signals for the gene probe divided by the number of
signals for the centromere reference probe. A case was
considered to be amplified if the gene/centromere ratio
was 2:1 or greater and deleted if the ratio was below
0.8:1, and otherwise normal. For explorative analysis, gene
amplification was defined by a ratio of 1.5:1 or greater and
gene deletion by a ratio below 0.9:1.
Statistical analysis
For statistical analysis, data were dichotomized into overall
genetic changes (amplification and deletion) and no genetic
changes of RRM1 or RRM2B, respectively. Combined
genetic status of RRM1 and RRM2B was dichotomized
as 2R aberrant (amplification and deletion of one or both
genes) and otherwise as 2R normal (normal copy number
status of both genes).
Associations between gene status and prognostic and
demographic variables of the main study [19] including
PAM50 intrinsic subtype (Jørgensen et al. manuscript pro-
visionally accepted for publication) were assessed. Asso-
ciations between gene status and categorical variables(regimen, hormone receptor status, human epidermal
growth factor receptor 2 (HER2) status, type of metastatic
site, stage of disease, previous chemo-, hormonal-, and
radio-therapy, and PAM50 intrinsic subtype) were evalu-
ated by Fisher’s exact test, whereas associations between
gene status and ordinal and interval variables (ECOG
performance status, age at randomization, number of
metastatic sites, and disease-free interval) were evaluated
by the Wilcoxon rank-sum test.
Time to progression (TTP) was the primary endpoint for
the original trial as well as for this biomarker sub-study
[19], and overall survival (OS) and response rate (RR) were
secondary endpoints. TTP was measured from random
assignment to date of documented progression with
censoring at date of last visit or at date of death. OS was
calculated from date of random assignment to date of death
with censoring for surviving patients at last visit date.
Time-to-event endpoints (TTP and OS) were estimated
by the Kaplan-Meier method, and association with gene
status was assessed by the log-rank test. Analyses of gene
status were done unadjusted and adjusted for preselected
covariates in multivariate Cox proportional hazards models.
The preselected covariates were those found to be sig-
nificant in the previous analysis of the main study [19]
including treatment regimen, disease type (visceral vs
nonvisceral), stage of disease, performance status, and
number of metastatic sites, in addition to PAM50 intrinsic
subtype (Jørgensen et al. manuscript provisionally accepted
for publication). The adjusted model was further stratified
for previous chemotherapy [19]. The assumption of pro-
portional hazards was assessed by Schoenfeld residuals.
Subgroup analyses were done to assess whether treatment
effects on TTP and OS varied according to gene status or
the levels of preselected covariates. The multivariate Cox
proportional hazards model was extended by one inter-
action term at a time and the interaction terms were tested
using the Wald test.
RR was evaluated for patients with measurable disease.
The overall RR was defined as a complete or partial
response according to RECIST criteria, version 1.0. RRs
were compared by using Fisher’s exact test.
Statistical analyses were conducted using the SAS version
9.2 software package (SAS Institute, Cary, NC, USA).
All statistical tests were two sided, and P <0.05 considered
statistically significant. Reporting Recommendations for
Tumor Marker Prognostic Studies (REMARK) were ad-
hered where applicable [24]. The design of the study is
prospective-retrospective as described in Simon et al. [25].
Results
For the present study FFPE primary tumor tissue was
available from 278 (82%) of the 337 patients enrolled in
the intention to treat population (Figure 1). FISH analysis
for RRM1 and RRM2B was successful in 261 (94%) and
Figure 1 Flow diagram of the presented study. *Patients were withdrawn for one of the following reasons: archival tissue not available
(n = 36), no tumor cells in available samples (n = 8), only needle biopsies available (n = 12), tissue samples available from metastasis only (n = 3).
Abbreviation: D, docetaxel; DBCG, Danish Breast Cancer Cooperative Group; FFPE, formalin-fixed, paraffin-embedded; GD, gemcitabine plus
docetaxel; FISH, fluorescence in situ hybridization; RRM1, ribonucleotide reductase M1 subunit; RRM2B, ribonucleotide reductase M2B subunit.
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tients (90%) had measurements of both genes and were
included in the prespecified prospective-retrospective
analysis.
Tumor tissue from patients who relapsed after primary
mastectomy or breast conserving surgery was available
from 229 (76%) compared to 22 (65%) from patients with
locally advanced disease at diagnosis. As a consequence
the 251 FISH assessable patients differed from the 86
non-assessable patients (P < 0.05) with regard to prior (neo)
adjuvant chemotherapy, adjuvant hormonal therapy, and
adjuvant radiotherapy, but not for other assessed parame-
ters (Additional file 1: Table S1).
The distribution of gene/centromere ratios are illustrated
in Figure 2. RRM1/CEN-11 ratios were found in the range
0.13-3.35 (Figure 2A), and RRM2B/CEN-8 ratios in the
range 0.43-7.33 (Figure 2B). Among the 251 patients, 38
patients (15.1%) had RRM1 deletions (Figure 3A) and 2
(0.8%) had RRM1 amplifications, whereas 8 patients (3.2%)
had RRM2B deletions and 26 (10.4%) had RRM2B am-
plifications (Figure 3B). A total of 7 patients (2.8%) had an
aberration of both genes (Table 1).
Patient and baseline characteristics according to RRM1,
RRM2B, and 2R status were assessed. No association was
found between RRM1 and RRM2B status, and RRM1 status
was not associated with any other factors (Additional file 2:
Table S2). RRM2B status was significantly associated with
median age at randomization (P = 0.03), bone metastases
(P = 0.03), HER2 status (P = 0.01), prior chemotherapy for
locally advanced or metastatic disease (P = 0.02) (Additional
file 2: Table S2), and PAM50 subtype (P = 0.0004) (Table 2).
All RRM2B aberrations except one were found in non-
luminal A cancers (Table 2). The 2R status was significantlyassociated with median age at randomization (P = 0.02),
stage of disease (P = 0.02), bone metastases (P = 0.02),
HER2 status (P = 0.04) (Additional file 2: Table S2), and
PAM50 subtype (P = 0.009) (Table 2).
RR did not differ significantly according to status of
RRM1, RRM2B or 2R (Table 3). However, a non-significant
trend of a better overall RR was seen in patients with
RRM1 aberrations (32% RRM1 normal; 50% RRM1 ab-
errant, P = 0.08).
In Kaplan-Meier analyses, RRM1, RRM2B or 2R status
were not significantly associated withTTP or OS (Figure 4).
The Cox proportional hazards model for TTP and OS
confirmed this result (Table 4). To meet the proportionality
assumption of the Cox model, the OS model for RRM1
was separated according to short time (0-1.5 years) and
long time prognosis (1.5-7.4 years). Patients with RRM1
aberrations tended to have a better OS in the time interval
0-1.5 years from randomization, though this difference
was not statistically significant (hazard ratio (HR) = 0.59,
95% confidence interval (CI) = 0.34-1.03, P = 0.06). In
contrary, RRM1 aberrations were significantly associated
with a poorer OS in the time interval 1.5-7.4 years (HR =
1.67, 95% CI = 1.06-2.62, P = 0.03). To test the independent
value of RRM1, RRM2B, and 2R status against standard
clinical and pathologic factors, multivariable Cox models
were constructed. RRM1 aberrations remained an inde-
pendent prognostic factor with an impact on OS from
1.5-7.4 years from randomization (HR = 1.72, 95% CI =
1.05-2.79, P = 0.03) (Table 4).
Treatment effect of GD versus D was comparable to the
effect in the original study with regard to TTP (adjusted
HR 0.56; 95% CI, 0.40-0.79, P = 0.001) and OS (HR 0.84;
95% CI, 0.64-1.12, P = 0.23) [19]. The subgroup analyses
Figure 2 Distribution of FISH ratios in the 251 FISH assessable
primary breast tumor samples. (A) Distribution of RRM1/CEN-11
ratios and (B) distribution of RRM2B/CEN-8 ratios. Abbreviation: CEN-8,
centromere of chromosome 8; CEN-11, centromere of chromosome
11; FISH, fluorescence in situ hybridization; RRM1, ribonucleotide
reductase M1 subunit; RRM2B, ribonucleotide reductase M2B subunit.
Figure 3 Photomicrographs demonstrating examples of RRM1
and RRM2B status in invasive breast tumors. Samples were
analyzed by FISH using Texas Red (RRM1 or RRM2B) and fluorescein
isothiocyanate (chromosome 11and 8) labeled probes (Leica DM
microscope, 100 × objective, oil emulsion). (A) Breast tumor with
RRM1 gene deletion (FISH ratio < 0.8). (B) Breast tumor with RRM2B
gene amplification (FISH ratio ≥ 2.0). Abbreviation: FISH, fluorescence
in situ hybridization; RRM1, ribonucleotide reductase M1 subunit;
RRM2B, ribonucleotide reductase M2B subunit.
Table 1 RRM1 and RRM2B status in 251 FISH assessable
primary tumor samples from advanced breast
cancer patients
RRM1
RRM2B Deletion Normal Amplification Total
Deletion 3 5 0 8 (3.2%)
Normal 31 184 2 217 (86.4%)
Amplification 4 22 0 26 (10.4%)
38 (15.1%) 211 (84.1%) 2 (0.8%) 251
Abbreviations: FISH fluorescence in situ hybridization, RRM1 ribonucleotide
reductase M1 subunit, RRM2B ribonucleotide reductase M2B subunit.
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OS endpoints according to RRM1 (TTP, Pinteraction = 0.35;
OS, Pinteraction = 0.50), RRM2B (TTP, Pinteraction = 0.60;
OS, Pinteraction = 0.63), or 2R (TTP, Pinteraction = 0.24; OS,
Pinteraction = 0.82).
The explorative definition of amplification and deletion
cut-points resulted in a higher proportion of RRM1 and
RRM2B aberrations but did not alter the results overall
(data not shown).
For assay validation 60 normal breast samples were ana-
lyzed for RRM1 and RRM2B gene copy number variation.
Neither amplifications nor deletions were found. For each
sample 60+ events (1 event = 1 red/gene signal) was evalu-
ated, with an average of 37.25 and 36.78 nuclei for RRM1
and RRM2B, respectively. An average of 1.62 red signals
representing the RRM1 genes and 1.55 green signals
representing the centromeric sequence were counted. TheRRM1/CEN-11 ratio varied from 0.92-1.20. An average of
1.64 red signals representing the RRM2B genes and 1.55
green signals representing the centromeric sequence were
counted. The RRM2B/CEN-8 ratio varied from 0.94-1.15.
Table 2 Association between RRM1, RRM2B, and 2R status and PAM50 intrinsic subtype
Characteristics RRM1 RRM2B 2R
Normal Aberrant Normal Aberrant Normal Aberrant
No. (%) No. (%) Pa No. (%) No. (%) Pa No. (%) No. (%) Pa
No. of patients 211 40 217 34 184 67
PAM50b 0.38 0.0004 0.009
Luminal A 63 (29.9) 8 (20.0) 70 (32.3) 1 (2.9) 62 (33.7) 9 (13.4)
Luminal B 74 (35.1) 15 (37.5) 75 (34.6) 14 (41.2) 62 (33.7) 27 (40.3)
Basal-like 32 (15.2) 10 (25.0) 35 (16.1) 7 (20.6) 27 (14.7) 15 (22.4)
HER2-enriched 37 (17.5) 7 (17.5) 33 (15.2) 11 (32.4) 29 (15.8) 15 (22.4)
Unknown 5 (0.0) 0 (0.0) 4 (1.8) 1 (2.9) 4 (2.2) 1 (1.5)
Abbreviations: 2R aberration RRM1 and/or RRM2B aberrant, 2R normal RRM1 and RRM2B both normal, HER2 human epidermal growth factor receptor 2, RRM1
ribonucleotide reductase M1 subunit, RRM2B ribonucleotide reductase M2B subunit.
a Fishers exact test, unknown values excluded from tests.
b PAM50: A 50-gene expression classifier that identifies the four major intrinsic subtypes of breast cancer known as the luminal A, luminal B, HER2-enriched and
basal-like subtypes [26].
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Discussion
This study demonstrated the existence of both deletions
and amplifications of RRM1 and RRM2B in primary breast
tumor samples, to our knowledge unprecedented in
human tumor tissue but in agreement with the frequently
observed somatic changes in the genome of breast cancer
cell lines [27-29]. RRM1 aberrations were demonstrated to
be a time-dependent prognostic factor with an impact on
OS, and RRM2B aberrations were significantly associated
with HER2 status and PAM50 subtype. In this study we
found no heterogeneity of treatment effects according to
RRM1 or RRM2B copy number status in terms of TTP or
OS. Combining RRM1 and RRM2B aberrations did not
add further information.Table 3 Best overall responsea by RRM1, RRM2B, and 2R statu
Response RRM1b
Normal Aberrant Normal
No. (%) No. (%) No.
CR 3 (2.3) 2 (7.1) 3
PR 39 (29.8) 12 (42.9) 45
Total responses 42 (32.0) 14 (50.0) 48
95% CI (24.2 to 40.8) (30.7 to 69.4) (27.1 to
SD 63 (48.1) 10 (35.7) 63
PD 18 (13.7) 1 (3.6) 15
Unknown 8 (6.1) 3 (10.7) 11
Total 131 28 137
Abbreviations: 2R aberration RRM1 and/or RRM2B aberrant, 2R normal RRM1 and RRM
disease, PR partial response, RRM1 ribonucleotide reductase M1 subunit, RRM2B ribo
aResponse rate was evaluated for patients with the presence of at least one measur
Tumors), version 1.0.
bTotal responses, Fishers exact test P = 0.08.
cTotal responses, Fishers exact test P = 1.00.
dTotal responses, Fishers exact test P = 0.46.We found deletions to be the most frequent gene copy
number variation in relation to RRM1. The RRM1 gene
resides at 11p15.5, a chromosomal region frequently associ-
ated with allelic loss in cancer [30,31] and agrees well with
the RRM1 deletions frequently observed in this study. Low
level of RRM1 in early-stage cancer patients treated with
surgery only has been associated with reduced survival
[32-35], whereas low RRM1 expression in gemcitabine-
treated advanced cancer patients has been associated with
improved survival [6,9]. The prognostic impact of RRM1
expression has not been confirmed in a randomized trial.
A prospective randomized phase III trial by Reynolds et al
(2009) [11] failed to demonstrate substantial difference in
survival according to RRM1 levels in lung cancer patients
treated with gemcitabine and carboplatin or gemcitabine
monotherapy. The retrospective biomarker sub-study of
another randomized phase III trial did not find a prognostics
RRM2Bc 2Rd
Aberrant Normal Aberrant
(%) No. (%) No. (%) No. (%)
(2.2) 2 (9.1) 2 (1.8) 3 (6.7)
(32.8) 6 (27.3) 36 (31.6) 15 (33.3)
(35.0) 8 (36.4) 38 (33.3) 18 (40.0)
43.7) (17.2 to 59.3) (24.8 to 42.8) (25.7 to 55.7)
(46.0) 10 (45.4) 54 (47.4) 19 (42.2)
(11.0) 4 (18.2) 14 (12.3) 5 (11.1)
(8.0) 0 (0.0) 8 (7.0) 3 (6.7)
22 114 45
2B both normal, CI confidence interval, CR complete response, PD progressive
nucleotide reductase M2B subunit, SD stable disease.
able lesion (n = 159) according to RECIST (Response Evaluation Criteria in Solid
Figure 4 (See legend on next page.)
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Figure 4 Time to progression (164 events) and overall survival (228 events) of patients according to RRM1, RRM2B, and 2R status. (A)
TTP according to RRM1 status. (B) OS according to RRM1 status. (C) TTP according to RRM2B status. (D) OS according to RRM2B status. (E) TTP
according to RRM1 and RRM2B status combined. (F) OS according to RRM1 and RRM2B status combined. Abbreviations: 2R aberration, RRM1
and/or RRM2B aberrant; 2R normal, RRM1 and RRM2B both normal; CI, confidence interval; OS, overall survival; RRM1, ribonucleotide reductase M1
subunit; RRM2B, ribonucleotide reductase M2B subunit; TTP, time to progression.
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lung cancer patients randomly assigned to cisplatin-based
chemotherapy including gemcitabine [13]. In the present
study RRM1 was demonstrated to be a time-dependent
prognostic factor with an impact on OS 1.5-7.4 years fromTable 4 Cox univariate and multivariate analysis for time to p
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and cancer type do compromise the comparability of
studies, and the prognostic significance of RRM1 in
advanced breast cancer remains to be further
elucidated.
Amplifications were the most common gene copy
number variation in relation to RRM2B observed in
this study. This is in agreement with the location of
RRM2B at 8q22.3 which is a chromosomal region
commonly characterized by DNA copy number gains
[27,36]. Several studies have pointed out that the gain of
8q is a recurrent event in sporadic breast cancer with
poor prognosis [36,37]. An association between RRM2B
expression and increased survival has been noticed in
lung and colon cancer [38-40], whereas an association
with poor prognosis has been observed in esophageal can-
cer patients [41]. RRM2B aberrations in this study did
not show any prognostic impact, in agreement with one
clinical study by Uramoto et al. (2006) [42] that found no
support for an association between RRM2B protein ex-
pression and survival outcome in stage I-III lung cancer
patients. Hence, there was a non-significant trend that
patients with RRM2B amplifications or deletions had
disease progression earlier than patients with normal
RRM2B status.
Moreover, the predictive value of RRM1 and RRM2B
in relation to gemcitabine-containing versus non-gemcita-
bine-containing therapy has not received much attention,
as only few and very small retrospective studies have com-
pared the effect of gemcitabine with a control/gemcitabine
naïve group [32]. More recently, an international phase
III trial that utilized levels of RRM1 to assign lung can-
cer patients to a gemcitabine-containing regimen if
RRM1 levels were low and a docetaxel-containing regi-
men if RRM1 levels were high versus a control arm of un-
selected chemotherapy consisting of carboplatin plus
gemcitabine, did not demonstrate a survival or response
rate benefit from individualizing therapy [43]. Our data
did not show a significant interaction between RRM1 and/
or RRM2B copy number status and outcome from adding
gemcitabine to docetaxel in terms of TTP or OS. An inter-
esting aspect in the context of the gemcitabine-taxane
chemotherapy combination could be the coexpression
of RRM1 and BRCA1 previously observed in metastatic
breast cancer specimens [44]. Where RRM1 low/nega-
tive expression has been connected to gemcitabine sensi-
tivity, decreased BRCA1 expression may enhance the
resistance to anti-microtubule agents [45]. Hence, the
clinical specimens investigated in this study may appear
suboptimal to provide results indicating an interaction
between RRM1 and the clinical outcome of gemcitabine.
RRM2B status was significantly associated with HER2
status. Almost 30% of the tumors with a RRM2B ab-
erration also had HER2 amplification. Several previousstudies have shown a nonrandom accumulation of
amplifications of different genomic regions in certain
breast cancers that are considered to show an ‘ampli-
fier’ phenotype [20,27,36,46,47]. Aberrations at the 8q22
locus are probably also part of a spectrum of breast car-
cinomas with high genomic instability and frequent ampli-
fications. In addition, this is in agreement with RRM2B
status being significantly associated with gene expres-
sion classified intrinsic subtype, as all but one aberra-
tion were seen to accumulate in the more proliferating
non-luminal A subtypes [20,21]. This is, however, in
contrast to RRM1 copy number variation, which was not
significantly different between the subtypes of breast can-
cer. A previous study by Kim et al. (2011) [48] where the
expression of RRM1 protein in breast cancer samples
was evaluated by immunohistochemical classification
reached the same conclusion. The relatively frequent aber-
rations observed in this study imply that RRM1 and
RRM2B are capable of contributing to breast cancer
development. The aberrations were not associated
suggesting that the aberrations characterize two distinct
geno-subtypes with different genetic pathways in the
evolution of invasive breast cancer.
The strengths of the study include data from more than
74% of the participants from a randomized trial, prospect-
ively defined hypotheses and analysis plan, long term
follow-up, biomarker analysis blinded from clinical out-
come, and outcome analysis by an independent statistical
core. However, the statistical power was limited due to the
small population size, especially under-powering the results
of the subgroup analysis. Furthermore, a potential limita-
tion concerns the fact that the predictive value of gene
aberrations is evaluated upon the primary tumor pro-
file, although the molecular portrait could have changed
pronouncedly between primary and metastatic disease
[49,50]. Moreover, one has to consider the limitations
of conclusions based on an evaluation at the genomic level
only. This study focused on gene copy number changes
without correlation with gene expression. Also, point
mutations, not detectable by the FISH assay utilized in
this study, could be of significant value [51,52], as well
as several factors but genetic alterations could influ-
ence the expression and activity of the enzyme pro-
teins, such as posttranscriptional and posttranslational
regulation.Conclusions
In summary, this study revealed the occurrence of RRM1
and RRM2B aberrations in primary breast tumor speci-
mens. We found no support of a differential outcome
according to these aberrations in advanced breast cancer
patients randomized to the combination of gemcitabine
and docetaxel as compared to docetaxel alone.
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